ArticleFrontiers in immunology2026
Severe immune checkpoint inhibitor-induced 3M syndrome: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have significantly improved survival rates in various advanced cancers, including cervical cancer. However, they can induce a range of immune-related adverse events (irAEs), with immune myocarditis being particularly dangerous, especially when combined with myositis and myasthenia gravis, forming the fatal 3M syndrome. Early symptoms are subtle, and delayed diagnosis and treatment often lead to severe consequences. Case presentation: A 65-year-old female with stage FIGO stage IIIA cervical squamous cell carcinoma received one dose of anti-PD-1 monoclonal antibody (Enlarzumab) combined with chemoradiotherapy. Following initial disease stabilization, the patient developed early neuromuscular symptoms, including ptosis and facial weakness, on Day 21. By Day 25, she experienced sudden chest tightness and acute heart failure with new-onset atrial fibrillation and a decline in left ventricular ejection fraction from 57% to 40%. The concurrent elevation of cardiac biomarkers and creatine kinase, alongside neuromuscular involvement, confirmed the clinical diagnosis of ICI-induced 3M syndrome. Despite treatment with high-dose methylprednisolone, intravenous immunoglobulin (IVIG), and mycophenolate mofetil, the patient ultimately succumbed to progressive respiratory failure following the family's decision to decline further invasive respiratory support. Conclusion: This case highlights the insidious onset and rapid progression of 3M syndrome, where neuromuscular symptoms often serve as overlooked precursors to myocarditis. Establishing a systematic approach involving proactive monitoring and immediate immunosuppressive treatment is essential to ensure the safety of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.